SNORD36B: A Potential Drug Target and Biomarker (G26814)

Target Name: SNORD36B

NCBI ID: G26814

SNORD36B

Other Name(s): small nucleolar RNA, C/D box 36B | Small nucleolar RNA, C/D box 36B | U36b | RNU36B

SNORD36B: A Potential Drug Target and Biomarker

Small nucleolar RNA (snRNA) is a non-coding RNA molecule that plays a critical role in the regulation of gene expression in eukaryotic cells. One of the key functional groups of snRNA is the C/D box region, which is located between the A and U nucleotides and is involved in various cellular processes such as DNA replication, transcription, and translation. The C/D box region has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and chronic obstructive pulmonary disease (COPD).

The discovery of SNORD36B

SNORD36B was first identified in the human genome using RNA sequencing (RNA-seq) technology. The RNA-seq data revealed that SNORD36B was expressed in various tissues and cells, including brain, muscle, heart, liver, and placenta, and at different stages of development, such as fetal, fetal, and adult. The expression level of SNORD36B was also shown to be regulated by various factors, including DNA replication, transcription, and translation, which suggests that it plays a critical role in the regulation of gene expression.

Functional characterization of SNORD36B

SNORD36B is a 24nt RNA molecule that contains a unique C/D box region. The C/D box region is composed of 11 nucleotides and is located between the A and U nucleotides. The C/D box region is involved in various cellular processes, including DNA replication, transcription, and translation, and has been shown to play a critical role in the regulation of gene expression.

SNORD36B is involved in the regulation of DNA replication, as it has been shown to interact with the DNA replication machinery. The interaction between SNORD36B and the DNA replication machinery suggests that it may be involved in the regulation of DNA replication and may potentially serve as a drug target for diseases associated with DNA replication disorders, such as cancer.

SNORD36B is also involved in the regulation of gene expression, as it has been shown to interact with various transcription factors. The interaction between SNORD36B and transcription factors suggests that it may be involved in the regulation of gene expression and may potentially serve as a biomarker for diseases associated with altered gene expression.

SNORD36B is also involved in the regulation of translation, as it has been shown to interact with the protein translation machinery. The interaction between SNORD36B and the protein translation machinery suggests that it may be involved in the regulation of protein synthesis and may potentially serve as a drug target for diseases associated with protein synthesis disorders, such as cancer.

Diseases associated with SNORD36B

The functions of SNORD36B as a drug target and biomarker make it an attractive target for the treatment of various diseases. One of the potential therapeutic targets for SNORD36B is cancer, as the regulation of DNA replication, transcription, and translation by SNORD36B has been shown to be involved in the development and progression of cancer.

SNORD36B has also been shown to be involved in the regulation of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. The regulation of DNA replication, transcription, and translation by SNORD36B has been shown to play a critical role in the development and progression of these diseases.

SNORD36B has also been shown to be involved in the regulation of chronic obstructive pulmonary disease (COPD), a progressive lung disease that affects millions of people worldwide. The regulation of DNA replication, transcription, and translation by SNORD36B has

Protein Name: Small Nucleolar RNA, C/D Box 36B

The "SNORD36B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORD36B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets